269 related articles for article (PubMed ID: 29108130)
1. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Hee Nam Y; Brensinger CM; Bilker WB; Flory JH; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2022 Jan; 111(1):218-226. PubMed ID: 34312836
[TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
6. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
[TBL] [Abstract][Full Text] [Related]
7. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
Leonard CE; Bilker WB; Brensinger CM; Han X; Flory JH; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
Clin Pharmacol Ther; 2016 May; 99(5):538-47. PubMed ID: 26566262
[TBL] [Abstract][Full Text] [Related]
8. Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.
Zhou M; Wang SV; Leonard CE; Gagne JJ; Fuller C; Hampp C; Archdeacon P; Toh S; Iyer A; Woodworth TS; Cavagnaro E; Panozzo CA; Axtman S; Carnahan RM; Chrischilles EA; Hennessy S
Epidemiology; 2017 Nov; 28(6):838-846. PubMed ID: 28682851
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
[TBL] [Abstract][Full Text] [Related]
10. Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin.
Nam YH; Brensinger CM; Bilker WB; Leonard CE; Han X; Hennessy S
Clin Pharmacol Ther; 2019 Jan; 105(1):210-218. PubMed ID: 29885251
[TBL] [Abstract][Full Text] [Related]
11. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
12. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
13. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
14. Individual sulfonylureas and serious hypoglycemia in older people.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
J Am Geriatr Soc; 1996 Jul; 44(7):751-5. PubMed ID: 8675920
[TBL] [Abstract][Full Text] [Related]
15. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
16. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
Vaughan EM; Rueda JJ; Samson SL; Hyman DJ
Curr Diabetes Rev; 2020; 16(8):851-858. PubMed ID: 32026779
[TBL] [Abstract][Full Text] [Related]
17. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
18. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
Romley JA; Gong C; Jena AB; Goldman DP; Williams B; Peters A
BMJ; 2015 Dec; 351():h6223. PubMed ID: 26643108
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
